Author

Andrea R. Hagemann

Washington University in St. LouisORCID 0000-0002-3484-0046Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

Brooke E. SandersiD· 3 shared Carolyn Kay McCourtiD· 3 shared David Gardner MutchiD· 3 shared Dineo KhabeleiD· 3 shared Ian S. HagemanniD· 3 shared Lindsay M. KurokiiD· 3 shared Mary Margaret MulleniD· 3 shared Matthew A. PowelliD· 3 shared

Activity by Year

2025-2025 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Brooke E. SandersORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 24, 2025

Targeting RAD52 overcomes PARP inhibitor resistance in preclinical Brca2-deficient ovarian cancer model

Yukihide Ota, Vijayalaxmi G. Gupta, Bisiayo Fashemi…·Dineo Khabele

This study identifies RAD52 as a target to overcome PARP inhibitor resistance in BRCA2-deficient ovarian cancer by showing its role in DNA repair and demonstrating synergistic effects with PARP inhibitors.

DOI 10.1101/2025.09.24.678351

mousebulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintAug 4, 2025

Targeting the COP9 signalosome overcomes platinum resistance in ovarian cancer through two distinct genome stability mechanisms

Elena Lomonosova, Megan Loeb, Kevin Rodriguez…·Mary Margaret Mullen

The paper identifies COPS5 as a therapeutic target for overcoming platinum resistance in ovarian cancer by inhibiting nucleotide excision repair and interstrand crosslink repair.

DOI 10.1101/2025.08.04.668450

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyJournal of Clinical InvestigationPeer-reviewedMay 20, 2025

Replication stress marker phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer

Angela M. Schab, Amanda J. Compadre, Rikki Drexler…·Mary Margaret Mullen

This study identifies phospho-RPA2 as a biomarker predicting response to platinum and PARP inhibitors in HR-proficient ovarian cancer, showing higher pathologic complete response and longer survival in pRPA2-High tumors.

11 citationstop 5%

humanimaging

𝕏 PostBluesky